Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

NCT01076543 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

110

Enrollment

NIH

Sponsor class

Conditions

AIDS-Related Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Follicular Lymphoma
Recurrent Lymphoplasmacytic Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Waldenstrom Macroglobulinemia

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide
DRUG: Temsirolimus

Sponsor

National Cancer Institute (NCI)